Metabolite identification in fecal microbiota transplantation mouse livers and combined proteomics with chronic unpredictable mild stress mouse livers

Bo Li1,2,3, Kenan Guo4, Li Zeng1,2, Benhua Zeng4, Ran Huo1,2,3, Yuanyuan Luo1,2,5, Haiyang Wang1,2, Meixue Dong1,2, Peng Zheng1,2,6, Chanjuan Zhou1,2, Jianjun Chen1,2, Yiyun Liu1,2, Zhao Liu1,2, Liang Fang5, Hong Wei2 and Peng Xie2,3,5,6,7

Abstract

Major depressive disorder (MDD) is a common mood disorder. Gut microbiota may be involved in the pathogenesis of depression via the microbe–gut–brain axis. Liver is vulnerable to exposure of bacterial products translocated from the gut via the portal vein and may be involved in the axis. In this study, germ-free mice underwent fecal microbiota transplantation from MDD patients and healthy controls. Behavioral tests verified the depression model. Metabolomics using gas chromatography–mass spectrometry, nuclear magnetic resonance, and liquid chromatography–mass spectrometry determined the influence of microbes on liver metabolism. With multivariate statistical analysis, 191 metabolites were distinguishable in MDD mice from control (CON) mice. Compared with CON mice, MDD mice showed lower levels for 106 metabolites and higher levels for 85 metabolites. These metabolites are associated with lipid and energy metabolism and oxidative stress. Combined analyses of significantly changed proteins in livers from another depression model induced by chronic unpredictable mild stress returned a high score for the Lipid Metabolism, Free Radical Scavenging, and Molecule Transports network, and canonical pathways were involved in energy metabolism and tryptophan degradation. The two mouse models of depression suggest that changes in liver metabolism might be involved in the pathogenesis of MDD. Conjoint analyses of fecal, serum, liver, and hippocampal metabolites from fecal microbiota transplantation mice suggested that aminoacyl-tRNA biosynthesis significantly changed and fecal metabolites showed a close relationship with the liver. These findings may help determine the biological mechanisms of depression and provide evidence about “depression microbes” impacting on liver metabolism.

Introduction

Major depressive disorder (MDD) is a debilitating mental disorder accounting for 12.3% of the global burden of disease and affects up to 15% of the general population1. Recent studies suggest that MDD is associated with neurotrophic alterations2, an imbalance in the hypothalamic–pituitary–adrenal axis3, and glutamine neurotransmitter system dysfunction4. Most research on depression focuses on changes to the brain, and few studies have examined the effects of liver metabolism on depression.
Accumulating evidence suggests that disruption of gastrointestinal microbes is associated with the development or exacerbation of mental disorders in humans, and the microbe–gut–brain axis may play a key role in maintaining brain health and stress responses2,27.

A mouse model of depression has been established using fecal microbiota transplantation (FMT), in which fecal matter from MDD patients is implanted into germ-free mice8,9. The germ-free mouse, which is free from bacterial contamination, has been widely used to investigate interactions between the microbiota and host10.

The liver is the main organ for substrate and energy metabolism and plays an important role in oxidative stress, glycogen storage, and the synthesis of secretory proteins. A previous study reported that liver diseases were associated with depression and suicide attempts11. Recently, metabolomics has been used to define metabolic disorders and specific biomarkers of various disease states12,13. We have applied metabolomics to the serum14, urine15, and peripheral blood mononuclear cells16 of MDD patients, and the prefrontal cortex of a lipopolysaccharide (LPS)-induced mouse model of depression17. During these studies, we identified five metabolites in urine from MDD patients uniquely produced by bacteria in the intestinal tract that were significantly decreased relative to healthy controls (CONs). Of note, some clinical studies have reported that MDD induced a relatively high incidence of irritable bowel syndrome, a disease involving saccharide (LPS)-induced mouse model of depression17. MDD patients were diagnosed following a structured psychiatric interview using DSM-IV-TR criteria and 17 items from the Hamilton depression rating scale. The FMT was carried out via randomly selecting 0.5 g of feces from five MDD or healthy individuals under an oxygen-free environment, and all 0.5 g samples were mixed in 7.5 mL of 0.9% saline to obtain suspension. Then the microbiota was transplanted into germ-free mice in a flexible film gnotobiotic isolator. After 2 weeks, behavioral tests were performed. On completion of behavioral tests, the livers of mice were immediately collected and stored at −80 °C until metabolism analysis.

**FMT and sample collection**

MDD patients were diagnosed following a structured psychiatric interview using DSM-IV-TR criteria and 17 items from the Hamilton depression rating scale. The FMT was carried out via randomly selecting 0.5 g of feces from five MDD or healthy individuals under an oxygen-free environment, and all 0.5 g samples were mixed in 7.5 mL of 0.9% saline to obtain suspension. Then the microbiota was transplanted into germ-free mice in a flexible film gnotobiotic isolator. After 2 weeks, behavioral tests were performed. On completion of behavioral tests, the livers of mice were immediately collected and stored at −80 °C until metabolism analysis.

**Gas chromatography–mass spectrometry**

Twenty-four mouse livers (12 MDD and 12 CON) were prepared for GC–MS metabolomics analysis. Briefly, a 100-mg liver sample was derivatized with pyridine hydrochloride solution and N,O-bis(trimethylsilyl)trifluoroacetamide (including 1% trimethylchlorosilane) before undergoing GC–MS analysis. Full details for derivatization and GC–MS conditions have been reported19. Analysis used the exported NetCDF file format and TagFinder. As an internal standard, L-2-chlorophenylalanine (0.03 mg/mL; methanol configuration) was used to normalize peak areas of extracted ions.

**Nuclear magnetic resonance**

Liver tissue (~100 mg) was mixed with 800 µL methanol–water (4:1, v/v) before being homogenized, ultrasonic extraction for 5 min, stewing for 20 min at 4 °C, and centrifugation at 14,000 g for 10 min at 4 °C. Supernatant (200 µL) was transferred to a glass bottle for rapid centrifugal concentrator volatile drying before being dissolved in 500 µL heavy water in a NMR tube prior to detection.

Proton spectra were detected using a Varian 600 spectrometer at an operating power of 599.925 MHz in 1H. A Carr–Purcell–Meiboom–Gill (recycle delay−90°−(τ−180°−τ)n−acquisition) pulse sequencer with a relaxation delay of 2.5 s, a mixing time of 100 m/s, a spectral width of 10 kHz, and a data point of 16 K was used cumulatively.
128 times. Discrimination between MDD and CON mice was visualized using partial least-squares discriminant analysis. Coefficient loading plots of the model were used to identify the spectral variables responsible for the sample differentiation on the score plot. A correlation coefficient of $|r| > 0.553$ based on a $p$-level $< 0.05$ or variable importance in projection (VIP) value $> 1.000$ was used as the cutoff value for statistical significance.

Liquid chromatography–mass spectrometry

LC–MS preparation was performed as previously described\(^9\). Briefly, 100 mg of liver sample was homogenized with 20 $\mu$L internal standard (l-2-chloro-L-phenylalanine, 0.03 mg/mL; methanol configuration) and 800 $\mu$L methanol–water solution (4/1, v/v) before ultrasonic extraction for 5 min, incubation for 20 min at 4 °C, and centrifugation for 10 min at 14,000 g at 4 °C. Supernatant (200 $\mu$L) was transferred into a glass bottle for LC–MS metabolomics analysis. Supernatant underwent ultra-performance liquid chromatography–tandem mass spectrometry (UPLC-Q-TOF/MS). Mass spectrometric data were collected using a Waters VION IMS Q-TOF mass spectrometer equipped with an electrospray ionization source operating in either positive or negative ion mode. Full details are provided in a previous study\(^9\). Orthogonal partial least-squares discriminant analysis (OPLS-DA) was used to identify differential metabolites in MDD mice compared with CON mice.

Metabolomics function and pathway analyses

For significantly altered metabolites ($p < 0.05$ and VIP $> 1.0$), pathway analyses was performed using MetaboAnalyst 3.0 (http://www.metaboanalyst.ca/) and Ingenuity pathway analysis (IPA) software. MetaboAnalyst is a comprehensive web application for metabolomics data analysis and interpretation. Metabolomics pathway analysis used several databases, including the Human Metabolome Database (HMDB; http://www.hmdb.ca/), Metlin (https://metlin.scripps.edu/), and the Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.genome.jp/kegg/), and the MetaboAnalyst tool, which can identify the most significantly changed metabolism pathways.

Molecular network analysis

Previous studies applying proteomics and metabolomics to the livers of chronic unpredictable mild stress (CUMS) mouse models of depression reported disturbed lipid metabolism and immune regulation\(^22,23\). In the current study, we cross-analyzed the two mouse models of depression using IPA. IPA is an advanced bioinformatics software program used to analyze biological pathways and functions of biomolecules of interest. The higher the score, the more relevant the molecules are to the network. The score is calculated using the right-tailed Fisher’s exact test and is based on hypergeometric distribution.

Results

Behavioral tests

Results of the behavioral tests are reported in our previous research\(^9\). Briefly, immobility times for the forced swimming test and the tail suspension test significantly increased and the center motion distance for the open-field test significantly decreased in “depression microbes” mice compared with “healthy microbes” mice, only behavioral significant changes mice used for further analysis. Using FMT, we constructed a mouse model of depression.

Metabolites showing a significant difference between MDD and CON mice

Metabolites from 12 MDD and 12 CON mice were used for OPLS-DA analysis. OPLS-DA score plots showed distinct separation between MDD mice and CON mice using the three metabolomics approaches (LC–MS$_{pos}$: R2Y = 0.868, Q2 = 0.683; LC–MS$_{neg}$:R2Y = 0.798, Q2 = 0.618; GC–MS: R2Y = 0.549, Q2 = −0.694; NMR: R2Y cum = 0.936, Q2 = 0.917) (Fig. 1). R2Y is the cumulative model variation in Y, and Q2 is the cumulative predicted variation. Values for these parameters approaching 1.0 indicate a stable model with predictive reliability. In the current study, R2Y and Q2 values indicated significant metabolic differences between MDD and CON mice. The original total ion chromatograms, typical base peak intensity chromatograms, and $^1$H Carr–Purcell–Meiboom–Gill NMR spectra are shown in Supplementary Fig. 1. A 199-iteration permutation test confirmed that OPLS-DA models were not over-fitted and were valid (Supplementary Fig. 2).

From OPLS-DA analysis, a total of 191 significantly different metabolites were identified between the MDD and CON mice using the three metabolomics approaches (106 decreased and 85 increased in the livers of MDD mice compared with CON mice). Details of the metabolites are shown in Table 1 and Supplementary Table 1.

Classification of the significantly changed metabolites

Using HMDB and MID for classification of metabolites according to their super class revealed that many belonged to the Lipid super class (linolenic acid, oxoproline, maltotriitol, arachidonic acid, 13-hydroxy-docosanoic acid) and the Amino acids, peptides and analogs super class (alanine, isoleucine, glutamine, valine, inominoacetic acid), as well as Carbohydrates and Carbohydrate Conjugates (glycogen, glutathione, D-arabitol), Aliphatic Acyclic Compounds (ethanolamine, trimethylamine
N-oxide, phosphocholine, urea) among others. A part of metabolites were clustering analyzed and emerged significantly different trends, especially in the Lipid super class (Fig. 2a). Lipid proportion >65% and Amino acids nearly 10% in all metabolites, the number of each class showed in Fig. 2b.

Metabolites analyzed between FMT and CON mice
The differential metabolites and their respective fold-change were analyzed using MetaboAnalyst, KEGG, and IPA to explore the potential effects of depression microbes. We identified nine pathways with a p-value < 0.05 that were different in MDD mice compared with
Table 1 Metabolites identified in livers extracts

| Metabolite/super class                  | VIP^a | FC   | r^b  | HMDB       | Platform | P-value^c | Trend^d |
|----------------------------------------|-------|------|------|------------|----------|-----------|---------|
| Aliphatic acyclic compounds            |       |      |      |            |          |           |         |
| Ethanolamine                           | 2.60  | –    | –    | HMD800149 | NMR      | –         | ↓       |
| Trimethylamine oxide                   | 2.63  | –    | –    | HMD800925 | NMR      | –         | ↓       |
| Phosphocholine                         | 1.89  | –    | –    | HMD801565 | NMR      | –         | ↑       |
| Urea                                   | 3.85  | 1.76 | –    | HMD800294 | GC–MS    | 0.04      | ↑       |
| Putrescine                             | 1.16  | 1.25 | –    | HMD801414 | GC–MS    | 0.03      | ↑       |
| Amino acids, peptides, and analogs     |       |      |      |            |          |           |         |
| Alanine                                | 1.46  | –    | –    | HMD800161 | NMR      | –         | ↑       |
| Glycine                                | 1.08  | –    | –    | HMD800123 | NMR      | –         | ↑       |
| Glycerol                               | 1.79  | –    | 0.64 | HMD800125 | NMR      | –         | ↑       |
| Hypoxanthine                           | –     | –    | 0.68 | HMD800157 | NMR      | –         | ↑       |
| Histidine                              | –     | –    | –0.90| HMD800177 | NMR      | –         | ↓       |
| Lysine                                 | 1.56  | –    | –    | HMD800182 | NMR      | –         | ↑       |
| Phosphocreatine                        | –     | –    | 0.59 | HMD801511 | NMR      | –         | ↑       |
| Iminodiacetate                         | 36.22 | –    | –0.98| HMD811753 | NMR      | –         | ↓       |
| Alanine                                | 5.44  | 1.24 | –    | HMD800161 | GC–MS    | 0.00      | ↑       |
| Proline                                | 3.20  | 1.25 | –    | HMD800162 | GC–MS    | 0.01      | ↑       |
| Isoleucine                             | 2.93  | 1.45 | –    | HMD800172 | GC–MS    | 0.01      | ↑       |
| Glutamine                              | 3.01  | 0.46 | –    | HMD800641 | GC–MS    | 0.00      | ↓       |
| Valine                                 | 3.80  | 1.39 | –    | HMD800883 | GC–MS    | 0.02      | ↑       |
| 3-Aminoisobutyric acid                 | 4.22  | 3.21 | –    | HMD803911 | GC–MS    | 0.00      | ↑       |
| Carbohydrates and carbohydrate conjugates |      |      |      |            |          |           |         |
| Glycogen                               | 2.74  | –    | –    | HMD800131 | NMR      | –         | ↑       |
| β-Glucose                              | 1.92  | –    | –    | HMD800516 | NMR      | –         | ↓       |
| Glutathione                            | –     | –    | 0.58 | HMD800757 | NMR      | –         | ↑       |
| α-Glucose                              | 3.55  | –    | –0.68| HMD803545 | NMR      | –         | ↓       |
| D-Arabitol                             | 1.27  | 2.19 | –    | HMD800568 | GC–MS    | 0.00      | ↑       |
| Galactitol                             | 14.68 | 0.59 | –    | HMD805826 | GC–MS    | 0.00      | ↓       |
| Nucleosides, Nucleotides, and Analogs  |       |      |      |            |          |           |         |
| Inosine                                | –     | –    | 0.58 | HMD800195 | NMR      | –         | ↑       |
| Uridine diphosphate–glucose            | –     | –    | 0.71 | HMD800286 | NMR      | –         | ↑       |
| Uridine                                | –     | –    | 0.61 | HMD800296 | NMR      | –         | ↑       |
| Lipids                                 |       |      |      |            |          |           |         |
| Linolenic acid                         | 1.29  | 1.44 | –    | HMD801388 | GC–MS    | 0.03      | ↑       |
| Oxoproline                             | 6.14  | 1.35 | –    | HMD808177 | GC–MS    | 0.00      | ↑       |
| Maltotriitol                           | 6.15  | 0.64 | –    | HMD815224 | GC–MS    | 0.00      | ↓       |
| Organic acids and derivatives          |       |      |      |            |          |           |         |
| Lactate                                | 2.42  | –    | –    | HMD862492 | NMR      | –         | ↑       |
| 3-Hydroxybutyrate                      | –     | –    | 0.63 | HMD800357 | NMR      | –         | ↑       |
Conclusions

The integration of proteomics and metabolomics using IPA software revealed significant changes in the metabolic pathways and glycerophospholipid metabolism. The disturbance of glycerophospholipid metabolism indicated oxidative stress, which was consistent with the findings of previous studies. The disturbance in the liver may play an important role in the pathophysiology of depression. The common pathway disturbance in liver may also indicate that the pathophysiology of depression is related to the condition of the liver.

System integrated analysis in FMT mice

From system integrated analysis of significant metabolites in the feces, serum, and hippocampal samples identified in a previous study, the amino acids asparagine, glutamine, isoleucine, proline, leucine, and glycine, which are involved in aminoacyl-tRNA biosynthesis, were most significantly altered. Details of the KEGG pathways are shown in Fig. 3a.

We also compared overlapping metabolites in different regions of FMT mice (Fig. 3b), and found that nine metabolites in the feces had a close association with the liver, and are mainly involved in energy and lipid metabolism (Supplementary Fig. 4).

Combined analysis of FMT and CUMS mice

Metabolites showing significant changes detected by LC-MS in livers from FMT and CUMS mice with minimum overlapping are listed in Fig. 3c. In super class, mainly of the metabolites belong to lipid. We analyzed metabolic pathways and glycerophospholipid metabolism was disturbed in FMT mice. Interesting to note that CUMS mice had the same change.

Glycerophospholipid is usually subdivided into phosphatidylethanolamine (PE), phosphatidylycholine (PC), phosphatidic acid (PA), and phosphoinositides (PS). PC species not only protects cells and their organelles from oxidative stress, but also is an essential component of biomembranes. PE species has been identified as modulator of inflammation. The disturbance of glycerophospholipid metabolism indicated oxidative stress, inflammatory cell membrane damage, and even apoptosis in the liver during FMT and CUMS. The common pathway disturbance in liver may play an important role in depression.

Molecular network analysis of FMT mice using IPA

A total of 191 metabolites and their respective fold-changes were subjected to molecular interaction network analysis using IPA software. Lipid Metabolism, Small Molecule Biochemistry, and Cellular Compromise were the most significantly changed network. A total of 21 metabolites, including 1-glutamine, linolenic acid, lysine, phosphorylcholine, urea, 1-proline, and glycogen, were associated with the network (Fig. 4).

Molecular network analysis of FMT and CUMS mice by IPA

In a study that undertook quantitative proteomics analysis of livers from the CUMS mouse model of depression, a total of 66 proteins were reported to exhibit significantly different expression.

We combined proteomics and metabolomics using IPA to examine the two models of depression, which showed behavioral changes stemming from different mechanisms.
Molecule Transports network had a high score of 99, and included high-density lipoprotein, low-density lipoprotein, the nuclear factor \( \kappa B \) signaling pathway (Supplementary Fig. 5). From canonical pathway analysis, we found that the overlap centered on Glycogen degradation and Tryptophan Degradation (Supplementary Fig. 6).

**Discussion**

Depression is a widespread and debilitating mental disorder that contributes to increased suicide rates and has a heavy socioeconomic burden; however, little is known about its pathogenesis. The gut microbiota is the largest ecosystem in the body and affects numerous physiological functions. The microbe–gut–brain axis is a communication system that integrates neural, hormonal, and immunological signals and metabolites between the gut and the brain\(^{25}\). Bacterial products, including lactic acid, organic acids, tryptophan, and propionic acid, have been shown to influence behavior in animals\(^{26}\), conjugated fatty acids, LPS, peptidoglycan, acylglycerols, sphingomyelin, and cholesterol can affect intestinal permeability and activate the intestine–brain–liver–neural axis to regulate glucose homeostasis\(^{27}\).

Research on depression usually focuses on the central nervous system and peripheral nervous system, rather than the liver. To the best of the authors’ knowledge, this is the first study to apply untargeted metabolomics approaches to the liver of a FMT mouse model of depression.

Liver has a unique vascular system and its blood mainly comes from intestine through the portal vein\(^{28}\). Due to the system, liver is vulnerable to exposure to bacterial products. Despite profound interindividual variability, Gram-negative bacteria, such as *Bacteroidetes,*...
**Enterobacteriaceae, Alistipes, and Proteobacteria** were strongly increased in MDD patients compared with the healthy individuals. Furthermore, increased LPS from Gram-negative bacteria induced endothelial hyperpermeability and "leaky gut" in MDD patients. The "leaky gut" increased translocation of gut-derived bacterial products and then stimulated innate immune system, which may involve in the pathophysiology of MDD. In this study, FMT from MDD patients may change gut permeability, hence, liver was exposed to bacterial products and presented disturbed metabolism profile.

In this study, we used three complementary techniques in our untargeted metabolomics approach, these being GC–MS, NMR, and LC–MS. Using these techniques, 191 differential metabolites were distinguished between mice livers treated with "depression microbes" and "healthy microbes". Importantly, just one metabolite (alanine) was identified by two approaches. The application of complementary approaches to metabolomics for the characterization of liver metabolism is of value. The metabolites identified included: (1) lipids (5-oxoproline and linolenic acid) and lipid metabolism-related molecules (α-glucose, β-glucose, and glycerol); (2) amino acids (glycine, proline, valine, isoleucine, lysine, and histidine); and (3) other metabolites (O-phosphorylethanolamine, putrescine, and trimethylamine N-oxide).

The amino acids, including glutamine, glycine, lysine, valine, and isoleucine, which had significantly changed in the mouse model of depression compared with CON mice. Some of these amino acids have an important role in brain function. Glutamine is a neurotransmitter that plays a crucial role in glutamatergic neurotransmission through contact with astrocytes and neurons in the glutamine–glutamate cycle. Preclinical research has reported that glutamine deficiency in the prefrontal cortex and cerebellum increased depressive-like behavior. We found that glutamine significantly decreased in peripheral blood mononuclear cells and the cerebellum of the mouse model of depression, suggesting that it could be a potential biomarker of depression. We also
conducted metagenomics using murine cecum feces from the same batch samples in this study, and relative abundance of the glutamate biosynthesis enzyme commission numbers showed a contrary trend\(^9\). The decrease in glutamine may suggest that microbes can affect liver glutamate levels and may modulate depressive-like behavior. The lysine level increased in MDD mice compared with CON mice. Recent studies report that lysine may affect neurotransmitters associated with anxiety and stress in the rat\(^{38}\), whereas lysine fortification reduces anxiety and lessens stress in humans\(^{39}\). Lysine is a constituent of the serotonin receptor 4 antagonist, which can reduce the level of blood cortisol and the microbe–gut–brain stress response in pigs\(^{40}\). In previous studies, we found that lysine levels decreased in the serum of MDD patients\(^{41}\), and in the cerebellum and prefrontal cortex of CUMS mice\(^{35,42}\). Accordingly, increasing lysine may combat depressive behavior and improve a person’s emotional status.

Metabolism research reports that valine levels decrease in peripheral blood mononuclear cells and the serum of drug-naïve MDD patients\(^{14,43}\). Similarly, alanine was reported to decrease in the serum of MDD patients, and may be a potential urine biomarker for MDD patients\(^{44}\).
In the current study, valine, isoleucine, and alanine increased in MDD mice liver. Levels of the three amino acids showed no difference among the serum, hippocampus, and feces. These results suggest that MDD patients and FMT mice accompanied amino-acid metabolism disturbed and the trends were not exactly same in different parts. The liver is the center for substrate and energy metabolism. Glucose is an important energy provider, and in the current study, it was found to be decreased in MDD mice compared with CON mice. Other metabolites involved in glycolysis and the tricarboxylic acid cycle were markedly downregulated, such as lactic acid. Combined IPA and canonical pathway analysis revealed glycogen degradation. These changes indicate a disturbance in energy metabolism. In agreement with previous research, a deficiency in circulating glucose was observed with serum and urine metabolomics studies of MDD patients. Also, levels of glucose were markedly decreased in the prefrontal cortex of LPS-induced mice. Blass et al. reported two clinical cases in which patients with symptoms of depression showed significant improvement in mood after 2 weeks administration of supplemental malic acid and glucose. Zheng et al. conducted a metabolomics analysis of feces and serum using the same FMT mouse model of depression and found increased levels of carbohydrate metabolites in MDD mice. Combining previous results with the results of the current study suggest that “depression microbes” may lead to a glucose disorder in liver. As the brain consumes 25% of the total glucose available in the body, the decrease in liver glucose may result in depressive behavior.

Phosphocreatine is a high-energy phosphate compound abundant in the central nervous system and functions as a transporter in cell energy exchange. It can transfer high-energy phosphate to ADP to provide ATP, generating creatine. Creatinine is a non-enzymatic by-product of creatine and phosphocreatine. In the current study, phosphocreatine showed a significant increase in the livers of MDD mice compared with CON mice. Zheng et al. reported that creatine in the serum of MDD patients was significantly decreased. We did not detect the secondary metabolite creatinine in the current study, but metabolism research has reported that creatinine in the urine of MDD patients and in the cerebellum of CUMS mice decreased. Upregulated phosphocreatine in the liver may be a compensatory energy source, providing beneficial help to improve depressive behavior.

The findings suggest that disturbances to glycolysis and the tricarboxylic acid cycle and the phosphocreatine–ATP pathway support previous research suggesting that a disturbance in energy metabolism may participate in the pathophysiology of depression, and the liver may play an important role.

Disturbances to oxidative stress are reported to be associated with the pathogenesis of MDD. In the current study, we found that the metabolites glycine and glutathione were significantly upregulated in MDD mice. These metabolites are involved in oxidative stress. As glutathione is the primary free radical scavenger in the brain, lower glutathione levels compromise central nervous system anti-oxidative activity. Additionally, lower levels of glutathione and oxidative damage could constitute early signaling events in cell apoptosis. Glycine has been suggested to be a member of glutathione biosynthesis. In our previous metabolism research using the same FMT mouse model of depression, we found that glutathione levels decreased in the prefrontal cortex and the cecum, and glycine decreased in the hippocampus. The metabolites in different parts may show different trends in diseased conditions. The elevated levels of glutathione in the liver suggest increased anti-oxidation activity, which may provide protection from oxidative stress in MDD mice.

Disturbances in lipid metabolism have been reported to be associated with geriatric depression in elderly patients and in rodent models of depression. In the current study, lipid-related molecules (a total of 126; 66% of all metabolites) showed a tendency to change in the livers of MDD mice. These molecules included O-phosphorylethanolamine, glycerol, and arachidonic acid. Glycerol is the final product of triglyceride metabolism. These findings suggest that MDD mice may have lipid metabolism dysregulation. Combined proteomics of CUMS mice livers showed a high score for the Lipid Metabolism, Free Radical Scavenging and Molecule Transports network. Furthermore, common fecal and liver metabolites appeared to show disturbed lipid metabolism. Disturbances in the metabolism of the three major nutrients in the MDD liver may account for the high comorbidity between MDD and metabolic syndrome.

This study has some limitations. The findings and conclusions drawn need to be treated cautiously because of the risk for overestimation with the relatively small sample size. Second, we did not validate quantities and species of microbes. The potential mechanism behind the association between microbes and liver metabolism disturbance is unclear. Further, data were obtained from naïve mice, additional studies should use an adult animal model of depression and conduct in vitro studies. Finally, we integrated information about metabolites trends from different depressive models, organs, and regions as far as possible. However, the potential relationships are not clear and need further research. In future study, we will focus on the mechanism of single strains inducing liver metabolism disturbance and the relationship between gut microbiota and depression.
Conclusion

In this study, we developed and analyzed a FMT mouse model of depression, and the findings contribute to previous studies on the involvement of the gut microbiota in psychiatric disorders. Using GC–MS, NMR, and LC–MS, we identified 191 changed metabolites in the MDD mouse liver compared with CON mice. The study mainly focused on three major disturbances in metabolism, these being associated with lipid, amino acid, and energy metabolism. Combined analyses with proteomics of CUMS mice livers showed a changed lipid network, suggestive of lipid disorders in the livers of mouse models of depression. Conjunctive analyses of metabolites in different parts of the FMT model suggested that aminoacyl-tRNA biosynthesis significantly changed and metabolites in feces were most closely associated with the liver. The findings suggest that "depression microbes" can disturb the liver and different parts of the body carrying out metabolic functions, and help determine the relationship between the liver, microbes, and depression. It is possible that treatment targeting microbes may be potential therapies for MDD.

Acknowledgements

This work was supported by the National Key R&D program of China (grant no. 2017YFA0507500, the National Key R&D program of China (grant no. 2016YFC0305700), the National Youth Science Foundation (grant no. 81601207), the China Postdoctoral Science Foundation (grant no. 2017M612923), the Natural Science Foundation Project of China (grant no. 81701360), the Chongqing Science & Technology Commission (CSTC2014JcyjA10004), and the Chongqing Science & Technology Commission (CSTC2017JCYJA0207). We thank Alexander Pischief, LLB, BMedSc, from Liwen Bianji, Edanz Group China (www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.

Author details

1Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China. 2Chongqing Key Laboratory of Neurobiology, Chongqing, China. 3Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), Chongqing, China. 4Department of Laboratory Animal Science, College of Basic Medical Sciences, Third Military Medical University, Chongqing, China. 5Department of Neurology, Yongchuan Hospital, Chongqing Medical University, Chongqing, China. 6Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 7South Australian Health and Medical Research Institute, Mind and Brain Theme, Flinders University, Adelaide, SA, Australia

Conflict of interest

The authors declare that they have no conflict of interest.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

accompanies this paper at https://doi.org/10.1038/s41398-017-0078-2.

Received: 8 August 2017 Revised: 1 November 2017 Accepted: 13 November 2017

Published online: 31 January 2018

References

1. Reynolds, E. H. Brain and mind: a challenge for WHO. Lancet 361, 1924–1925 (2003).
2. Guilloux, J. P. et al. Molecular evidence for BNDF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. Mol. Psychiatry 17, 1130–1142 (2012).
3. Haj-Mirzaian, A. et al. Lithium attenuated the depressive and anxiogenic effect of juvenile social stress through mitigating the negative impact of interleukin-1beta and nitric oxide on hypothalamic-pituitary-adrenal axis function. Neuroscienc 315, 271–285 (2016).
4. Mitchell, N. D. & Baker, G. B. An update on the role of glutamate in the pathophysiology of depression. Acta Psychiatr. Scand. 122, 192–210 (2010).
5. Rogers, G. E. et al. From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Mol. Psychiatry 21, 738–748 (2016).
6. Hober, A. E. et al. Regulation of prefrontal cortex myelination by the microbiota. Transl. Psychiatry 6, e774 (2016).
7. Moloney, R. D., Desbonnet, L., Clarke, G., Dinan, T. G. & Cryan, J. F. The microbiome stress, health and disease. Mamm. Genome 25, 49–74 (2014).
8. Zeng, L. et al. Microbiota modulates behavior and protein kinase C mediated cAMP response element-binding protein signaling. Sci. Rep. 6, 20998 (2016).
9. Zheng, P. et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism. Mol. Psychiatry 21, 786–796 (2016).
10. Cryan, J. F. & Dinan, T. G. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat. Rev. Neurosci. 13, 701–712 (2012).
11. Le Strat, Y., Le Foll, B. & Dubertret, C. Major depression and suicide attempts in patients with liver disease in the United States. Liver Int 35, 1910–1916 (2015).
12. Nicholson, J. K. & Lindon, J. C. Systems biology: metabonomics. Nature 455, 1054–1056 (2008).
13. Q. Y. et al. Urinary metabolite markers of precocious puberty. Mol Cell Proteomics 11, M111.01072(2012).
14. Zheng, P. et al. Plasma metabonomics as a novel diagnostic approach for major depressive disorder. J. Prote. Res. 11, 1741–1748 (2012).
15. Chen, J. J. et al. Divergent urinary metabolic phenotypes between major depressive disorder and bipolar disorder identified by a combined GC-MS and NMR spectroscopic metabolic approach. J. Prote. Res. 14, 3382–3389 (2015).
16. Li, J. et al. Peripheral blood mononuclear cell-based metabolic profiling of a chronic unpredictable mild stress rat model of depression. Mol. Biost. 10, 2994–3001 (2014).
17. Wu, Y. et al. Metabolic analysis reveals metabolic disturbances in the prefrontal cortex of the lipopolysaccharide-induced mouse model of depression. Behav. Brain Res. 308, 115–127 (2016).
18. Ladep, N. G., Obindo, T. J., Audu, M. D., Okie, E. N. & Malu, A. O. Depression in patients with intractable bile syndrome in Jos, Nigeria. World J Gastroenterol. 12, 7844–7847 (2007).
19. Chen, J. J. et al. Combined application of NMR- and GC-MS-based metabonomics yields a superior urinary biomarker panel for bipolar disorder. Sci. Rep. 4, 5555 (2014).
20. Bozatray, S. et al. The human urine metabolome. PLoS ONE 8, e73076 (2013).
21. Liu, Y. et al. Metabonomics study of esential hypertension and its chinese medicine subtypes by using gas chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy. Eva. Based Complement. Altern. Med. 2013, 625906 (2013).
22. Wu, Y. et al. Quantitative proteomics analysis of the liver reveals immune regulation and lipid metabolism dysregulation in a mouse model of depression. Behav. Brain Res. 311, 330–339 (2016).
23. Já, H. M. et al. Chronic unpredictable mild stress leads to altered hepatic metabolic profile and gene expression. Sci. Rep. 6, 23441 (2016).
24. Devaux, P. F. Static and dynamic lipid asymmetry in cell membranes. Biochemistry 30, 1163–1173 (1991).
25. Mayer, E. A. Gut feelings: the emerging biology of gut-brain communication. Nat. Rev. Neurosci. 12, 453 (2011).
26. Hanstock, T. L., Mallet, P. E. & Clayton, E. H. Increased plasma D-lactic acid associated with impaired memory in rats. Physiol. Behav. 101, 653–659 (2010).
27. Gaboian, C. et al. Central insulin regulates heart rate and arterial blood flow: an endothelial nitric oxide synthase-dependent mechanism altered during diabetes. Diabetes 56, 2872–2877 (2007).
28. Seki, E. & Schnabl, B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the Liver and gut. J. Physiol. 590, 447–458 (2012).
29. Caballero, S. & Pamer, E. G. Microbiota-mediated inflammation and anti-microbial defense in the intestine. Annu. Rev. Immunol. **33**, 227–256 (2015).
30. Kiecolt-Glaser, J. K., Dery, H. M. & Fagundes, C. P. Inflammation: depression fans the flames and feasts on the heat. Am. J. Psychiatry **172**, 1075–1091 (2015).
31. Chatterjee, A. et al. Heat shock protein 90 inhibitors attenuate LPS-induced endothelial hyperpermeability. Am. J. Physiol. Lung. Cell. Mol. Physiol. **294**, 755–763 (2008).
32. Maes, M., Kubera, M. & Leunis, J. C. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro. Endocronol. Lett. **29**, 117–124 (2008).
33. Eid, T., Tu, N., Lee, T. S. & Lai, J. C. Regulation of astrocyte glutamine synthetase like behaviours in male mice. J. Psychiatry Neurosci. **38**, 183–191 (2013).
34. Lee, Y. et al. Glutamine deficiency in the prefrontal cortex increases depressive-like behaviours in mouse. J. Psychiatry Neurosci. **38**, 183–191 (2013).
35. Shao, W. H. et al. Combined metabolomics and proteomics analysis of major depression in an animal model: perturbed energy metabolism in the chronic mild stressed rat cerebellum. OMICS **19**, 383–392 (2015).
36. Li, J. et al. Potential antidepressant and resilience mechanism revealed by metabolomic study on peripheral blood mononuclear cells of stress resilient rats. Behav. Brain. Res. **320**, 12–20 (2016).
37. Yang, P. et al. Alterations of amino acid level in depressed rat brain. Korean J. Physiol. Pharmacol. **18**, 371–376 (2014).
38. Smriga, M. & Torii, K. L-lysine acts like a partial serotonin receptor 4 antagonist and inhibits serotonin-mediated intestinal pathologies and anxiety in rats. Proc. Natl. Acad. Sci. USA **100**, 15370–15375 (2003).
39. Smriga, M., Ghosh, S., Mounejine, Y., Pellett, P. L. & Scrimshaw, N. S. Lysine fortification reduces anxiety and lessens stress in family members in economically weak communities in Northwest Syria. Proc. Natl. Acad. Sci. USA **101**, 8268–8273 (2004).
40. Sinrongkote, S., Smriga, M., Nakagawa, K. & Torii, Y. A diet fortified with L-lysine and L-arginine reduces plasma cortisol and blocks anxiogenic response to transportation in pigs. Nutr. Neurosci. **6**, 283–289 (2003).
41. Xu, H. B. et al. Potential clinical utility of plasma amino acid profiling in the detection of major depressive disorder. Psychiatry Res. **200**, 1054–1057 (2012).
42. Liu, L. et al. The identification of metabolic disturbances in the prefrontal cortex of the chronic restraint stress rat model of depression. Behav. Brain. Res. **305**, 148–156 (2016).
43. Liu, M. L. et al. Severe disturbance of glucose metabolism in peripheral blood mononuclear cells of schizophrenia patients: a targeted metabolomic study. J. Transl. Med. **13**, 226 (2015).
44. Zheng, P. et al. Identification and validation of urinary metabolite biomarkers for major depressive disorder. Mol. Cell. Proteom. **12**, 207–214 (2013).
45. Blass, J. P. Nutritional supplement for cerebral metabolic insufficiencies. US (2003).
46. Michel, T. M., Pulschen, D. & Thome, J. The role of oxidative stress in depressive disorders. Curr. Pharm. Des. **18**, 5890–5899 (2012).
47. Gawryluk, J. W. et al. Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia. Int. J. Neuropsychopharmacol. **14**, 1069–1074 (2011).
48. Schulz, J. B., Lindenau, J., Seyfried, J. & Dichgans, J. Glutathione, oxidative stress and neurodegeneration. Eur. J. Biochem. **267**, 4904–4911 (2000).
49. Paige, L. A., Mitchell, M. W., Krishnan, K. R., Kaddurah-Daouk, R. & Steffens, D. C. A preliminary metabolic analysis of older adults with and without depression. Int. J. Geriatr. Psychiatry **22**, 418–423 (2007).
50. Chen, G. et al. Amino acid metabolic dysfunction revealed in the prefrontal cortex of a rat model of depression. Behav. Brain. Res. **278**, 286–292 (2015).
51. Vaccarino, V. et al. Depression, the metabolic syndrome and cardiovascular risk. Psychosom. Med. **70**, 40–48 (2008).